Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.75 |
| ▸ | HPGD | P15428 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.75 |
| ▸ | PHGDH | O43175 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455965 | 1.00 | ALDH1A1 (0.75) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL13611475 | 0.87 | MAPT (0.71) | ALDH1A1HPGDLMNAALOX12MAPT | |
| SCHEMBL21292670 | 0.86 | PHGDH (0.80) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL21292759 | 0.86 | ALDH1A1 (1.00) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL4455860 | 0.85 | PHGDH (0.77) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL13886982 | 0.85 | PHGDH (0.77) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL4343479 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL13611582 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL12879871 | 0.83 | PHGDH (0.56) | ALDH1A1HPGDLMNAALOX12PHGDH | |
| SCHEMBL4328162 | 0.82 | MAPT (0.79) | ALDH1A1HPGDLMNAALOX12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | PEKING UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | PEKING UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2019-08-29 | — | — | US | disclosed |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2019-08-29 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | MDH2, MDH1, DLD | ALDH1A1 447/4885HPGD 199/4885LMNA 3928/4885 |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | ALDH1A1 1459/4885HPGD 1646/4885LMNA 4884/4885 |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | MDH2, MDH1, DLD | ALDH1A1 447/4885HPGD 199/4885LMNA 3928/4885 |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | MDH2, MDH1, DLD | ALDH1A1 447/4885HPGD 199/4885LMNA 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.